Information Provided By: 
Fly News Breaks for November 15, 2018
ALNY
Nov 15, 2018 | 07:59 EDT
After hosting a dinner with Alnylam CEO John Maraganore and the company's management, Stifel analyst Paul Matteis said management "exudes confidence" that Onpattro can penetrate a substantial portion of the diagnosed haTTR population while acknowledging that it takes a little time to convert "start forms" into paying commercial patients. Management also seems "completely at ease" ahead of the full readout of the givosiran phase 3 ENVISION data, said Matteis, who keeps a Buy rating and $111 price target on Alnylam shares.
News For ALNY From the Last 2 Days
ALNY
Apr 23, 2024 | 07:17 EDT
ProQR Therapeutics (PRQR) announced the Annual General Meeting, AGM, of Shareholders will take place on Wednesday, May 22, 2024 at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands. As part of the AGM, Martin Maier, PhD, is nominated for appointment as a non-executive Board Member for a period of four years. Dr. Maier is Senior Vice President Research heading the Oncology group at Alnylam Pharmaceuticals (ALNY).
